Skin Cancer Foundation Position: Nicotinamide (a form of vitamin B3) could help prevent skin cancer. The Skin Cancer Foundation comments on forthcoming research findings from Australia New York, NY (May 15, 2015) — Australian researchers recently released a study abstract revealing that Nicotinamide, a form of vitamin B3, significantly reduces the incidence of nonmelanoma skin cancers among people who have had a previous basal cell carcinoma or squamous cell carcinoma.
The researchers conducted a year-long study of 386 people, who averaged 66 years old. Half of the people in the study took 500 milligrams of Nicotinamide (Vitamin B3) twice a day and the other half were put on a placebo. The researchers found that people who took vitamin B3 twice a day cut their chances of developing new skin cancers by 23 percent. “The results of this study are certainly promising, but we believe that more research is needed to determine whether or not to recommend vitamin B3 therapy for skin cancer prevention,” said Skin Cancer Foundation Senior Vice President Deborah S. First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint. ChromaDex Corp.
(OTCQX: CDXC) announced today that the initial results of the first human clinical study for the company's NIAGEN® nicotinamide riboside (NR) has met its primary endpoint. The results demonstrated that a single dose of NR resulted in statistically significant increases in the co-enzyme nicotinamide adenine dinucleotide (NAD+) in healthy human volunteers. The study shows for the first time a similar conversion of NR into NAD+ as has been shown in prior animal studies. Maintenance of sufficient levels of NAD+ is key to cellular energy metabolism and mitochondrial function. If NAD+ levels go down or are redirected (as in cancer cells), mitochondrial function erodes, creating numerous adverse effects. In the first human clinical study of NIAGEN®, NAD+ metabolomic analyses were completed in blood for various time points over a 24-hour period. The full results of the study will be submitted for peer review in the scientific literature. Dr. Nobel Laureate Dr. Don't believe the HYPE about Nicotinamide Riboside (Niagen)
Niagen is the brand name of the only commercially available form of Nicotinamide Riboside, sometimes referred to as NR, Vitamin NR, or the God Vitamin.
Several companies are promoting Nicotinamide Riboside using their own product name, but ALL use the exact same ingredient. ALL Nicotinamide Riboside (Niagen) is Identical – It ALL comes from Chromadex Patents on the commercial production of NR are controlled by Chromadex. They are the ONLY SOURCE. Some brands portray their product as unique, and often don’t use the name Niagen. They prefer you don’t know there are many other brands that have the exact same Nicotinamide Riboside at a much lower cost. Novel Vitamin Discovery Offers Clues for Cancer Chemotherapy and Lipid Disorders. For Release: May 13, 2004 Contact: DMS Communications (603) 650-1492 Novel Vitamin Discovery Offers Clues for Cancer Chemotherapy and Lipid Disorders HANOVER, NH-Dartmouth Medical School cancer researchers, in a fusion of biochemistry and genetics, have discovered a new vitamin in a molecular pathway central to such vital processes as gene regulation, metabolism and aging.
And, they found that milk contains this nutrient. The work, published in the May 14 issue of Cell, defines another metabolic route to a compound called NAD and suggests that therapeutic approaches for cancer or heart disease may depend on the enzymes discovered. NAD (nicotinamide adenine dinucleotide) is one of the most well-known small molecules in the cell, said Dr. NAD is a co-enzyme for hundreds of cellular enzymes. Their findings upend some assumptions underlying biosynthetic schemes for NAD that have been in textbooks for decades and refocus the cancer pharmacology of tiazofurin and benzamide riboside. Derivative of vitamin B3 prevents liver cancer in mice. Liver cancer is one of the most frequent cancers in the world, and with the worst prognosis; according to the World Health Organisation (WHO), in 2012, 745,000 deaths were registered worldwide due to this cause, a figure only surpassed by lung cancer.
The most aggressive and frequent form of liver cancer is hepato-cellular carcinoma (HCC); little is known about it and there are relatively few treatment options.